| Literature DB >> 23953899 |
Abstract
Vitamin K antagonists have been in wide use for over 70 years. Warfarin, the most commonly used vitamin K antagonist, has been shown to be highly effective in treating and preventing thrombosis. Despite this, warfarin has many disadvantages, which has led to the development of a new class of oral anticoagulants targeted to specific coagulation factors designated as target-specific oral anticoagulants (TSOAs). TSOAs include the thrombin inhibitors (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban). This chapter reviews the disadvantages of warfarin and evaluates both the advantages and disadvantages of the new oral anticoagulants.Entities:
Keywords: apixaban; dabigatran; oral anticoagulation; rivaroxaban; vitamin K antagonists; warfarin
Mesh:
Substances:
Year: 2013 PMID: 23953899 DOI: 10.1016/j.beha.2013.07.009
Source DB: PubMed Journal: Best Pract Res Clin Haematol ISSN: 1521-6926 Impact factor: 3.020